Open AccessComplete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6‐NTRK3 gene fusion
Author(s) -
Pitoia Fabián
Publication year - 2021
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.3900
Subject(s) - medicine , papillary thyroid cancer , trk receptor , thyroid cancer , refractory (planetary science) , fusion gene , thyroid , cancer research , surgery , oncology , pathology , gene , neurotrophin , receptor , physics , astrobiology , biochemistry , chemistry
Larotrectinib, a highly selective TRK inhibitor, was administered to a patient with rapidly progressing radioactive iodine‐refractory papillary NTRK3 fusion‐positive thyroid cancer. The patient achieved a durable (sustained for 11 months) complete response after 2 months of treatment and complete intracranial responses in metastatic brain lesions after 7 months of treatment. Larotrectinib may provide a therapeutic route for patients with RAI‐R‐differentiated thyroid cancer who might otherwise have few treatment options.